Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Sucampo Pharma Inc (SCMP) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart


See More
  • Market Capitalization, $K 708,180
  • Shares Outstanding, K 45,830
  • Annual Sales, $ 153,180 K
  • Annual Income, $ 33,370 K
  • 36-Month Beta 1.74
  • Price/Sales 4.62
  • Price/Book 4.89

Price Performance

See More
Period Period Low Period High Performance
11.30 +40.93%
on 11/08/16
17.55 -9.26%
on 11/30/16
+4.57 (+40.31%)
since 11/04/16
10.60 +50.24%
on 11/02/16
17.55 -9.26%
on 11/30/16
+4.41 (+38.36%)
since 09/06/16
9.59 +66.06%
on 03/17/16
18.75 -15.07%
on 12/23/15
-0.78 (-4.64%)
since 12/04/15

Most Recent Stories

More News
5 Best Small-Cap Stocks for 2017

Investing in small cap stocks with superior fundamentals will make for a profitable choice even in 2017.

Bristol-Myers Reports Data from Opdivo Combination Studies

Bristol-Myers (BMY) presented multiple data from Opdivo combination studies.

GW Pharma (GWPH) Posts Narrower-than-Expected Q4 Loss

GW Pharmaceuticals (GWPH) reported a narrower-than-expected loss of 89 cents per share in the fourth quarter of fiscal 2016 (ended Sep 30, 2016).

Acceleron, Celgene Present Myelodysplastic Syndromes Data

Acceleron (XLRN) and Celgene (CELG) announced updated data from the ongoing phase II studies on luspatercept in myelodysplastic syndromes patients.

Alexion Presents Data from Ultra-Rare Blood Disorder Study

Alexion Pharmaceuticals (ALXN) presented new data from a dose-escalation study on ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria at ASH.

What Makes Concordia International (CXRX) a Strong Sell?

Concordia International (CXRX) has witnessed a significant price decline and negative trend in earnings estimate revisions

Heat Biologics Stock Falls on Negative Bladder Cancer Data

Heat Biologics (HTBX) presented disappointing top-line phase II data from the bladder cancer study on its lead pipeline candidate, HS-410.

Achaogen (AKAO) Catches Eye: Stock Adds 6.5% in Session

Achaogen, Inc. (AKAO) moved big last session, as its shares jumped over 6% on the day.

Cytori Scleroderma Study Two-Year Follow-Up Data Published

Cytori Therapeutics (CYTX) announced the publication of two year follow-up data from the scleroderma study.

PhaseRx Soars on Orphan Drug Status for Rare Liver Disease

PhaseRx (PZRX) received Orphan Drug status from the FDA for PRX-OTC for the treatment of rare liver disorder.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones...

See More

Support & Resistance

2nd Resistance Point 16.25
1st Resistance Point 16.00
Last Price 15.90
1st Support Level 15.35
2nd Support Level 14.95

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.